{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Relapse"},{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"4"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"title":"Not evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"* A complete response (CR) will be defined as less than 5% bone marrow blasts in the setting of a neutrophil count of \\>/= 1.0 K/ul and a platelet count of \\>/= 75,000/ul\n* A complete response except platelets (CRp) will be defined as less than 5% bone marrow blasts in the setting of a neutrophil count of \\>/= 1.0 K/ul and a platelet count of \\>/= 75,000/ul\n* A partial response (PR) will be defined as 5%-25% bone marrow blasts in the setting of a neutrophil count of \\>/= 1.0 K/ul and a platelet count of \\>/= 75,000/ul\n* A partial response except platelets (PRp) will be defined as 5%-25% bone marrow blasts in the setting of a neutrophil count of \\>/= 1.0 K/ul and a platelet count of \\>/= 75,000/ul","groups":[{"description":"This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).","id":"OG000","title":"Dose Level 1: Clofarabine at 20 mg/m^2/Dose x 5 + THIO-MEL"},{"description":"This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).","id":"OG001","title":"Dose Level 2: Clofarabine at 30 mg/m^2/Dose x 5 + THIO-MEL"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Response to Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}